Product Data Sheet

BMN 673



Cat. No.:	A4153
CAS No.:	1207456-01-6
Formula:	C19H14F2N6O
M.Wt:	380.35
Synonyms:	
Target:	DNA Damage/DNA Repair
Pathway:	PARP
Storage:	Store at -20°C

Solvent & Solubility

In Vitro

insoluble in H2O; ⩾14.2 mg/mL in EtOH with gentle warming and ultrasonic; ⩾19.02 mg/mL in DMSO

Preparing Stock Solutions

Mass / Solvent / Concentration	1mg	5mg	10mg
1 mM	2.6292 mL	13.1458 mL	26.2916 mL
5 mM	0.5258 mL	2.6292 mL	5.2583 mL
10 mM	0.2629 mL	1.3146 mL	2.6292 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary	Potent PARP inhibitor
IC_{50} & Target	0.58 nM (PARP)

In Vitro

Cell Viability Assay

Cell Line:	SCLC cell lines
Preparation method:	Limited solubility. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.
Reacting conditions:	24 h-96 h

	Applications:	BMN 673 exhibits a potent inhibitory effect on a panel of 11 SCLC cell lines (IC50=1.7 to 15 nmol/L), which are all within clinically achievable ranges. In addition, sensitivity to BMN673 correlates to DNA repair protein expression and PI3K pathway activity.
In Vivo	**Animal experiment**	
	Animal models:	Nude mice bearing established subcutaneous MX-1 tumor xenografts.
	Dosage form:	Oral gavage and twice daily for 28 consecutive days.
	Applications:	BMN 673 inhibits the growth of MX-1 xenografts in mice, with 4 of 6 mice achieving a complete response. 0.33 and 0.1 mg/kg BMN 673 is well tolerated, with no animal lethality.
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

Product Citations

See more customer validations on www.apexbt.com.

References

1. Shen Y, Rehman FL, Feng Y et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res. 2013 Sep 15;19(18):5003-15.
2. Cardnell RJ, Feng Y, Diao L et al. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. Clin Cancer Res. 2013 Nov 15;19(22):6322-8.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com